Please call the Pharmacy Medicines Unit on or for a copy.

Size: px
Start display at page:

Download "Please call the Pharmacy Medicines Unit on or for a copy."

Transcription

1

2 Title: PATIENT GROUP DIRECTION FOR THE SUPPLY OF CHLORAMPHENICOL EYE DROPS 0.5% UNDER THE MINOR AILMENT SERVICE Identifier: Across NHS Boards Organisation Wide Directorate Clinical Service Sub Department Area This controlled document shall not be copied in part or whole without the express permission of the author or the author s representative. Review date: July 2008 Author: Policy application: Alison Strath Scottish Executive NHS Scotland Caroline Hind NHS Grampian NHS Grampian Purpose: This Patient Group Direction (PGD) authorises appropriately qualified Community Pharmacists registered as members of the Royal Pharmaceutical Society to supply chloramphenicol eye drops 0.5% to individuals without the requirement for a patient specific prescription written by a medical practitioner. Responsibilities for implementation: Organisational: Local Policy statement: Review: NHS Grampian Pharmacy Medicines Unit Community pharmacy contractors It is the responsibility of individual pharmacists and their managers (where applicable) to ensure that they work with the terms laid down in this PGD and that pharmacists using this PGD act within their own level of competence. This policy will be reviewed in two years or sooner if current treatment recommendations change. This policy is also available in large print and on computer disk. Other formats can be supplied on request. Please call the Pharmacy Medicines Unit on or for a copy.

3 PATIENT GROUP DIRECTION FOR THE SUPPLY OF CHLORAMPHENICOL EYE DROPS 0.5% UNDER THE MINOR AILMENT SERVICE A Patient Group Direction is a specific written instruction for the supply or administration of named medicines in an identified clinical situation. It is drawn up locally by Doctors, Pharmacists and other appropriate professionals, approved by the Employer and advised by the relevant professional advisory committees. In most cases, appropriate clinical care is provided on an individual basis by a specific prescriber to a specific individual patient. Patient Group Directions should only be considered where they offer a benefit to patient care without compromising patient safety in any way. Effective from 1 st July 2006 Review date July 2008

4 PATIENT GROUP DIRECTION FOR THE SUPPLY OF CHLORAMPHENICOL EYE DROPS 0.5% UNDER THE MINOR AILMENT SERVICE 1 Introduction This patient group direction (PGD) is designed to guide pharmacists on the supply of chloramphenicol eye drops 0.5% under the Minor Ailment Service (MAS). This will allow pharmacists to dispense a POM pack of chloramphenicol under PGD. Acute bacterial conjunctivitis will give the patient a sensation of a gritty, uncomfortable eye or eyes, with possibly a purulent or watery discharge, or crusting of the eyelid margins occurs because of the discharge, usually after sleep. It will only have been present for a few days and is not associated with any reduction in vision. The affected eye(s) will often look slightly red / infected, but this is not usually very marked. Severe pain is not a feature of simple conjunctivitis. 2 Clinical Decision Making 2.1 Patients who may be considered for the supply of chloramphenicol eye drops 0.5% Patients presenting in Community Pharmacy with a need for treatment of symptoms of bacterial conjunctivitis, and registered for the Minor Ailment Service (MAS). 2.2 Patients who may receive the supply of chloramphenicol eye drops 0.5% All patients in 2.1 above, who do not want specifically to consult a doctor and are willing to have treatment from the pharmacist. Patients over 1 year of age. 2.3 Consent Prior to the supply of chloramphenicol eye drops 0.5%, consent must be obtained either from the patient, parent or guardian. There is no legal requirement for consent to be in writing but written consent does serve to provide a permanent record that the individual (patient, parent or guardian) has been informed about the process, benefits and risks of chloramphenicol eye drops 0.5%. Individuals (patient, parent or guardian) should also be informed about how data will be stored, who will be able to access that information and how that data may be used. If a patient s fitness and suitability cannot be established, supply should be deferred and the patient referred to their doctor. Written and verbal information should be available in a form that can be easily understood by the person who will be giving the consent. Where English is not easily understood, translations and properly recognised interpreters should be used.

5 2.4 Consent for supply to children. A patient under 16 years of age may give consent, provided he or she understands fully the benefits and risks involved. The patient should be encouraged to involve a parent/guardian, if possible, in the decision. For young children not competent to give or withhold consent, such consent can be given by a person with parental responsibility. 2.5 Contraindications Patients may not receive a supply of chloramphenicol eye drops 0.5% if they: are under 1 year of age. are pregnant. are breast-feeding. have a known hypersensitivity or a previous adverse reaction to chloramphenicol, benzalkonium chloride or disodium edetate. 2.6 Patient Referral Urgent referral: - if painful, rather than just uncomfortable or gritty - if reduced visual acuity - if eye looks cloudy - if pus level visible in anterior chamber - if any history of trauma to eye, immediately prior to onset of symptoms - if possibility of foreign body on/in eye - if history of welding without eye protection immediately prior to onset of symptoms - if no improvement within 48 hours - if there is marked redness of the eye Routine referral: - pregnancy - breast-feeding 2.7 Action to be taken when a patient is excluded from treatment under this PGD Patients should be referred to their doctor where they are excluded from treatment in Action to be taken when a patient does not wish to receive treatment under this PGD The patient should be referred to their doctor. 2.9 Concurrent medication Patients should be advised to allow at least 5 minutes between administration of two different eye drop preparations.

6 3 Designated Staff Authorised to Supply Chloramphenicol Eye Drops 0.5% Community Pharmacists registered as members of the Royal Pharmaceutical Society of Great Britain are authorised to use the PGD for the supply of chloramphenicol eye drops 0.5% under the Minor Ailments Service. It is important to note that the above professionals may only supply or administer medicines under a PGD as named individuals. In addition the following requirements are necessary. Staff must: agree to be professionally accountable for their work (Appendix 1). be aware of current treatment recommendations. have appropriate experience and competence to identify and recommend treatment for bacterial conjunctivitis. have access to the current PGD for chloramphenicol eye drops 0.5% under the Minor Ailments Service. maintain their skills and knowledge in this area according to their individual Code of Professional Conduct. agree to work within the terms of the NHS Grampian PGD. be familiar with the RPSGB Practice Guidance: OTC chloramphenicol eye drops. The Director of Pharmacy and Medicines Management will be responsible for: Ensuring that the current PGD for chloramphenicol eye drops 0.5% is available to community pharmacists providing care under this PGD. Maintaining a current record of all pharmacists authorised to supply chloramphenicol eye drops 0.5% under this PGD. 4 Description of Treatment Available Under this Direction 4.1 Presentation Chloramphenicol eye drops 0.5% 10mL pack. Description and excipients can vary with manufacturer. Chloramphenicol eye drops 0.5% are a Prescription Only Medicine (POM). 4.2 Dose, route and frequency Adults and children 1 year and over Ocular administration: Apply one (1) drop every two (2) hours for the first 48 hours then reduce frequency to 4 hourly as infection is controlled. To be used during waking hours only. The course of treatment is 5 days. Use for at least 48 hours after healing, up to a maximum of 5 days.

7 4.3 Adverse effects Occasional : Transient stinging on instillation. Rare : Allergic reaction (persistent burning, swelling of lids) Also see current BNF. In the event of a Suspected Adverse Drug Reaction, please complete a Yellow card and submit to the MHRA. A Yellowcard can be found at the rear of the BNF. Record findings, advice and actions in person s record Medical advice in cases of anaphylaxis 4.4 Advice to patient Medical advice must be sought as soon as possible from a doctor if any patient develops any signs of hypersensitivity. If there is a delay in medical support arriving and the condition of the patient is deteriorating then an emergency ambulance must be called on 999. Provide Patient Information Leaflet. Contact lenses to be removed during period of treatment. Contact lens wearers should be advised to follow strict hand hygiene. Hard contact lenses or disposable contact lenses may be replaced after successful treatment. Soft contact lenses should not be replaced until 24 hours after successful treatment. Measures to reduce spread of infection/do not allow the end of the dropper to touch the eye/do not share towels/hand cleanliness etc. Continue for 48 hours after healing. Store in a fridge (2-8º), and keep cap tightly closed between applications. Discard after course of treatment. Warn of possibility of blurred vision which may affect driving/operating machinery. Consult with a doctor if no improvement in 48 hours or if symptoms worsen. Packs are for individual patient use do not share bottles. 4.5 Follow up treatment Not applicable 5 Documentation 5.1 Authorisation of supply under PGD The following staff are authorised to supply chloramphenicol eye drops 0.5% without a medical prescription, under MAS, providing the patient falls into one of the categories listed in 2.2 of this PGD. Staff must be employed either directly by NHS Grampian, or contracted to provide NHS services, or providing services in partnership with NHS Grampian under the direction of this authorised PGD Registered pharmacists as recognised by RPSGB

8

9 Appendix 1 HEALTH CARE PROFESSIONAL AGREEMENT TO SUPPLY MEDICINES UNDER PATIENT GROUP DIRECTION I: Based at: agree to supply medicines under the direction contained within the following Patient Group Direction PATIENT GROUP DIRECTION FOR THE SUPPLY OF CHLORAMPHENICOL EYE DROPS 0.5% UNDER THE MINOR AILMENT SERVICE I have completed the appropriate training to my professional standards enabling me to supply medicines under the above Patient Group Direction. I agree not to act beyond my professional competence nor outwith the recommendations of the Patient Group Direction. Signed: Print name: Date: RPSGB No

10 Appendix 2 CERTIFICATE OF COMPETENCE TO SUPPLY MEDICINES UNDER PATIENT GROUP DIRECTION This authorises: Based at: To supply medicines under the following Patient Group Direction PATIENT GROUP DIRECTION FOR THE SUPPLY OF CHLORAMPHENICOL EYE DROPS 0.5% UNDER THE MINOR AILMENT SERVICE The above named person has satisfied the training requirements and is competent to supply medicines under the above Patient Group Direction. The above named person has agreed not to act beyond their professional competence nor outwith the recommendations of the Patient Group Direction Signed: Professor George Downie Director of Pharmacy and Medicines Management Date:

SUPPLY OF CHLORAMPHENICOL EYE DROPS 0.5% UNDER THE MINOR AILMENT SERVICE

SUPPLY OF CHLORAMPHENICOL EYE DROPS 0.5% UNDER THE MINOR AILMENT SERVICE NHS LANARKSHIRE PATIENT GROUP DIRECTION SUPPLY OF CHLORAMPHENICOL EYE DROPS 0.5% UNDER THE MINOR AILMENT SERVICE Effective date : 1 July 2008 Review date : 30 June 2010 P1 Name of Medicine : Chloramphenicol

More information

SUPPLY OF CHLORAMPHENICOL EYE DROPS 0.5% UNDER THE MINOR AILMENT SERVICE

SUPPLY OF CHLORAMPHENICOL EYE DROPS 0.5% UNDER THE MINOR AILMENT SERVICE NHS LANARKSHIRE PATIENT GROUP DIRECTION SUPPLY OF CHLORAMPHENICOL EYE DROPS 0.5% UNDER THE MINOR AILMENT SERVICE Effective date : 1 Nov 2015 Review date : 30 Nov 2017 P1 Name of Medicine : Chloramphenicol

More information

Author of PGD: Adrian MacKenzie, Lead Pharmacist, Community Pharmacy.

Author of PGD: Adrian MacKenzie, Lead Pharmacist, Community Pharmacy. Patient Group Direction for the supply of Chloramphenicol 0.5% eye drops to named patients registered with the Minor Ailment Service attending Community Pharmacies in NHS Borders This document authorises

More information

THIS PATIENT GROUP DIRECTION HAS BEEN APPROVED on behalf of NHS Fife by:

THIS PATIENT GROUP DIRECTION HAS BEEN APPROVED on behalf of NHS Fife by: Patient Group Direction for Named Community Pharmacists to Supply CHLORAMPHENICOL EYE DROPS 0.5% To patients aged 1 year and older Under the Minor Ailments Service. Number 114 Issued October 2016 Issue

More information

appropriate healthcare professionals employed at my pharmacy. I understand that I am

appropriate healthcare professionals employed at my pharmacy. I understand that I am Patient Group Direction: For the supply of Silver Sulfadiazine 1% Cream by Community Pharmacists in Somerset to patients for the topical treatment of minor localised impetigo under the Somerset Minor Ailments

More information

Package leaflet: Information for the user. GENTAMICIN VISION 3 mg/ml eye drops, solution Gentamicin

Package leaflet: Information for the user. GENTAMICIN VISION 3 mg/ml eye drops, solution Gentamicin Package leaflet: Information for the user GENTAMICIN VISION 3 mg/ml eye drops, solution Gentamicin Read all of this leaflet carefully before you start taking this medicine because it contains important

More information

Minims Chloramphenicol

Minims Chloramphenicol Minims Chloramphenicol Eye Drops Chloramphenicol Eye Drops Consumer Medicine Information What is in this leaflet This leaflet answers some common questions about Minims Chloramphenicol, including how to

More information

Submission for Reclassification

Submission for Reclassification Submission for Reclassification Fucithalmic (Fusidic Acid 1% Eye Drops) From Prescription Medicine to Restricted Medicine (Pharmacist Only Medicine) CSL Biotherapies (NZ) Limited 666 Great South Road Penrose

More information

PRESCRIBING INFORMATION

PRESCRIBING INFORMATION PRESCRIBING INFORMATION Pr PENTAMYCETIN Chloramphenicol Ophthalmic Solution USP 0.25%, 0.5% Chloramphenicol Ophthalmic Ointment USP 1% Antibiotic Pr PENTAMYCETIN/HC Chloramphenicol and Hydrocortisone Eye

More information

PACKAGE LEAFLET: INFORMATION FOR THE USER. GENTAMICIN VISION 3 mg/g eye ointment Gentamicin

PACKAGE LEAFLET: INFORMATION FOR THE USER. GENTAMICIN VISION 3 mg/g eye ointment Gentamicin PACKAGE LEAFLET: INFORMATION FOR THE USER GENTAMICIN VISION 3 mg/g eye ointment Gentamicin Read all of this leaflet carefully before you start using this medicine. - Keep this leaflet. You may need to

More information

PRODUCT INFORMATION CHLORSIG

PRODUCT INFORMATION CHLORSIG PRODUCT INFORMATION CHLORSIG NAME OF DRUG CHLORSIG EYE DROPS contains 0.5% w/v chloramphenicol. CHLORSIG EYE OINTMENT contains 1.0% w/w chloramphenicol. The structural formula of chloramphenicol (CAS -

More information

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT CYTOPOINT 10 mg solution for injection for dogs CYTOPOINT 20 mg solution for injection for dogs CYTOPOINT 30 mg

More information

The active component of CHLOROMYCETIN eye ointment is chloramphenicol.

The active component of CHLOROMYCETIN eye ointment is chloramphenicol. PRODUCT INFORMATION CHLOROMYCETIN EYE OINTMENT chloramphenicol 10 mg per g NAME OF THE MEDICINE The active component of CHLOROMYCETIN eye ointment is chloramphenicol. OHH O 2 N C - C - CH 2 OH H NHCOCHC

More information

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Purevax RCPCh lyophilisate and solvent for suspension for injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION

More information

Delayed Prescribing for Minor Infections Resource Pack for Prescribers

Delayed Prescribing for Minor Infections Resource Pack for Prescribers Delayed Prescribing for Minor Infections Resource Pack for Prescribers Background: Antibiotic resistance is an alarming threat to modern healthcare, and infectious illness remains a major global threat

More information

New Zealand Consumer Medicine Information

New Zealand Consumer Medicine Information New Zealand Consumer Medicine Information FLUCLOXACILLIN Flucloxacillin (as the sodium salt) 250 mg and 500 mg capsules Flucloxacillin (as the sodium salt) 125 mg/5 ml and 250 mg/5 ml powder for oral solution

More information

Collagen cross-linking after-care instructions

Collagen cross-linking after-care instructions Patient information Collagen cross-linking after-care instructions After collagen cross-linking, you have a soft bandage contact lens in place for seven s. You have been given several different drops and

More information

Package leaflet: Information for the user. HYDROCORTISON CUM CHLORAMPHENICOL 5 mg/g + 2 mg/g eye ointment hydrocortisone acetate, chloramphenicol

Package leaflet: Information for the user. HYDROCORTISON CUM CHLORAMPHENICOL 5 mg/g + 2 mg/g eye ointment hydrocortisone acetate, chloramphenicol Package leaflet: Information for the user HYDROCORTISON CUM CHLORAMPHENICOL 5 mg/g + 2 mg/g eye ointment hydrocortisone acetate, chloramphenicol Read all of this leaflet carefully before you start using

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS Issued March 2017 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Recicort 1.77 mg/ml + 17.7 mg/ml ear drops, solution for dogs and cats Recicort vet 1.77 mg/ml + 17.7 mg/ml

More information

LABELLING AND PACKAGE LEAFLET

LABELLING AND PACKAGE LEAFLET LABELLING AND PACKAGE LEAFLET 1 A. LABELLING 2 PARTICULARS TO APPEAR ON THE OUTER PACKAGE CARTON BOX 1. NAME OF THE VETERINARY MEDICINAL PRODUCT MILTEFORAN 20 mg/ml oral solution for dogs miltefosine 2.

More information

SUMMARY OF PRODUCT CHARACTERISTICS 1.B.1 SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS 1.B.1 SUMMARY OF PRODUCT CHARACTERISTICS 1.B. SUMMARY OF PRODUCT CHARACTERISTICS 1.B.1 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Lamox 800 mg/g powder for use in drinking water for chickens and pigs 2. QUALITATIVE

More information

November 2017 Review Nov Signatures of those developing the Patient Group Direction Job Title Name Signature Date Doctor Stephanie Dundas

November 2017 Review Nov Signatures of those developing the Patient Group Direction Job Title Name Signature Date Doctor Stephanie Dundas Supply of Trimethoprim 200mg tablets by Community Pharmacists for the Management of Uncomplicated Urinary Tract Infections in Female Patients from 16 and 65 years of age. November 2017 Review Nov 2019

More information

PROFESSIONAL PRACTICE STANDARD

PROFESSIONAL PRACTICE STANDARD PROFESSIONAL PRACTICE STANDARD Dispensing Drugs TBD Introduction Under the Veterinarians Act and Regulations, veterinarians licensed by the College of Veterinarians of Ontario are authorized to engage

More information

Summary of Product Characteristics

Summary of Product Characteristics Summary of Product Characteristics 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Pro Penstrep Suspension for Injection for Cattle, Sheep and Pigs. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains:

More information

Summary of Product Characteristics

Summary of Product Characteristics Summary of Product Characteristics 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Dipen 100ml Suspension for Injection for cattle, sheep and pigs 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Active Substance

More information

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT COXEVAC suspension for injection for cattle and goats 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains:

More information

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Eurican Herpes 205 powder and solvent for emulsion for injection. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Active

More information

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT BLUEVAC BTV8 suspension for injection for cattle and sheep 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml of

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Marbocare 20 mg/ml solution for injection for cattle and pigs (UK, IE, FR) Odimar 20 mg/ml solution for injection for cattle

More information

B. PACKAGE LEAFLET 1

B. PACKAGE LEAFLET 1 B. PACKAGE LEAFLET 1 PACKAGE LEAFLET FOR: Cadorex 300 mg/ml solution for injection for cattle, sheep and pigs 1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION

More information

Package leaflet: Information for the user

Package leaflet: Information for the user Text draft from 12.07.2018 Minoxidil BIO-H-TIN-Pharma 20 mg/ml Page 1 Package leaflet: Information for the user Minoxidil BIO-H-TIN-Pharma 20 mg/ml cutaneous spray, solution Minoxidil For women aged over

More information

SUMMARY OF PRODUCT CHARACTERISTICS. Cephacare flavour 50 mg tablets for cats and dogs. Excipients: For a full list of excipients, see section 6.1.

SUMMARY OF PRODUCT CHARACTERISTICS. Cephacare flavour 50 mg tablets for cats and dogs. Excipients: For a full list of excipients, see section 6.1. SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Cephacare flavour 50 mg tablets for cats and dogs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains: Active

More information

Developed By Name Signature Date

Developed By Name Signature Date Patient Group Direction 2196 version 1.0 Administration / Supply of Amoxicillin in Patients presenting with Acute Severe Sinusitis / Acute Otitis Media by Registered employed by Torbay and South Devon

More information

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS. Medicinal product no longer authorised

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS. Medicinal product no longer authorised ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Zubrin 50 mg oral lyophilisates for dogs Zubrin 100 mg oral lyophilisates for dogs Zubrin 200 mg oral lyophilisates

More information

B. PACKAGE LEAFLET 1

B. PACKAGE LEAFLET 1 B. PACKAGE LEAFLET 1 PACKAGE LEAFLET NICILAN 400 mg/100 mg tablets for dogs 1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH

More information

Job Title Name Signature Date

Job Title Name Signature Date Supply of Trimethoprim 200mg tablets By Community Pharmacists for the Management of Uncomplicated Urinary Tract Infections in Female Patients Protocol number 473 Version 1 Date protocol prepared: November

More information

LABELLING AND PACKAGE LEAFLET A. LABELLING

LABELLING AND PACKAGE LEAFLET A. LABELLING LABELLING AND PACKAGE LEAFLET A. LABELLING DATA TO BE MARKED ON THE EXTERIOR OF THE PACKAGING DATA TO BE MARKED ON THE DIRECT PACKAGING DESCRIPTION AND TYPE OF THE PACKAGING 1. NAME OF THE VETERINARY MEDICAL

More information

SUMMARY OF PRODUCT CHARACTERISTICS. Bottle of powder: Active substance: ceftiofur sodium mg equivalent to ceftiofur...

SUMMARY OF PRODUCT CHARACTERISTICS. Bottle of powder: Active substance: ceftiofur sodium mg equivalent to ceftiofur... SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT WONDERCEF powder and solvent for solution for injection for horses not intended for the production of foods for human consumption.

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Covexin 10 Suspension for injection for sheep and cattle 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Active substances Potency

More information

PATIENT INFORMATION LEAFLET DYNA CEFPODOXIME 100 mg / DYNA CEFPODOXIME SUSPENSION:

PATIENT INFORMATION LEAFLET DYNA CEFPODOXIME 100 mg / DYNA CEFPODOXIME SUSPENSION: SCHEDULING STATUS S4 PROPRIETARY NAME, STRENGTH AND PHARMACEUTICAL FORM: DYNA CEFPODOXIME 100 mg (film coated tablet) DYNA CEFPODOXIME SUSPENSION (powder for oral suspension) Please read this leaflet carefully

More information

[Version 7.2, 12/2008] ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

[Version 7.2, 12/2008] ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS [Version 7.2, 12/2008] ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT RABORAL V-RG 2. QUALITATIVE AND QUANTITATIVE COMPOSITION For 1 dose: Active substance: -

More information

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Porcilis ColiClos suspension for injection for pigs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each dose of 2 ml

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS Revised: January 2012 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Blackleg Vaccine 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Active substance(s): per ml Five strains

More information

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS [Version 7.3.1, 11/2010] FINAL SPC, LABELLING AND PACKAGE LEAFLET ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT CEVAC Clostridium Ovino suspension for injection

More information

Irish Medicines Board

Irish Medicines Board IRISH MEDICINES BOARD ACT 1995 EUROPEAN COMMUNITIES (ANIMAL REMEDIES) (No. 2) REGULATIONS 2007 (S.I. No. 786 of 2007) VPA: 10999/056/001 Case No: 7004318 The Irish Medicines Board in exercise of the powers

More information

SFJCCZJ1 Monitor and maintain the health, well-being and safety of dogs

SFJCCZJ1 Monitor and maintain the health, well-being and safety of dogs Monitor and maintain the health, well-being and safety of dogs Overview This unit is about looking after the health, well-being and safety of dogs that are used in the custodial context and being alert

More information

Metacam 1.5 mg/ml oral suspension for dogs

Metacam 1.5 mg/ml oral suspension for dogs Metacam 1.5 mg/ml oral suspension for dogs Species:Dogs Therapeutic indication:pharmaceuticals: Neurological preparations: Analgesics, Other NSAIDs, Locomotor (including navicular and osteoarthritis) Active

More information

Withdrawal period: 93 days Milk: Not authorised for use in animals producing milk for human consumption.

Withdrawal period: 93 days Milk: Not authorised for use in animals producing milk for human consumption. A. LABELLING PARTICULARS TO APPEAR ON THE OUTER PACKAGE AND THE IMMEDIATE PACKAGE CARTON BOX AND LABELS OF 100 ml and 250 ml 1. NAME OF THE VETERINARY MEDICINAL PRODUCT TILKOMAY 300 mg/ml + 90 mg/ml solution

More information

Ubroseal Dry Cow 2.6 g intramammary suspension for cattle

Ubroseal Dry Cow 2.6 g intramammary suspension for cattle Health Products Regulatory Authority 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Ubroseal Dry Cow 2.6 g intramammary suspension for cattle 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each 4g intramammary

More information

The Implications of the Shift from Prescribing to OTC use of Chronic Medications

The Implications of the Shift from Prescribing to OTC use of Chronic Medications The Implications of the Shift from Prescribing to OTC use of Chronic Medications Dr John Blenkinsopp Senior Research Fellow Department of Medicines Management Keele University www.blenkinsopp.co.uk www.impactdetailing.org.uk

More information

Package leaflet: Information for the patient. FLUCLOXACILLIN 250MG/5ML ORAL SOLUTION Flucloxacillin

Package leaflet: Information for the patient. FLUCLOXACILLIN 250MG/5ML ORAL SOLUTION Flucloxacillin Package leaflet: Information for the patient FLUCLOXACILLIN 250MG/5ML ORAL SOLUTION Flucloxacillin Read all of this leaflet carefully before you start taking this medicine because it contains important

More information

BOX 1. NAME OF THE VETERINARY MEDICINAL PRODUCT. Hymatil 300 mg/ml solution for injection for cattle and sheep Tilmicosin

BOX 1. NAME OF THE VETERINARY MEDICINAL PRODUCT. Hymatil 300 mg/ml solution for injection for cattle and sheep Tilmicosin BOX 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Hymatil 300 mg/ml solution for injection for cattle and sheep Tilmicosin 2. STATEMENT OF ACTIVE AND OTHER SUBSTANCES Each ml contains: Tilmicosin 300 mg;

More information

New PGD. This direction was authorised on: Oct The direction will be reviewed by: Oct Author of PGD: Anne Duguid, Antimicrobial Pharmacist

New PGD. This direction was authorised on: Oct The direction will be reviewed by: Oct Author of PGD: Anne Duguid, Antimicrobial Pharmacist Patient Group Direction for the supply of Trimethoprim 200mg tablets for the treatment of women with uncomplicated urinary tract infections by Pharmacists working within NHS Borders Community Pharmacies.

More information

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT CLYNAV solution for injection for Atlantic salmon 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each 0.05 ml dose

More information

V E T E R I N A R Y C O U N C I L O F I R E L A N D ETHICAL VETERINARY PRACTICE

V E T E R I N A R Y C O U N C I L O F I R E L A N D ETHICAL VETERINARY PRACTICE V E T E R I N A R Y C O U N C I L O F I R E L A N D ETHICAL VETERINARY PRACTICE ETHICAL VETERINARY PRACTICE The term Ethical Veterinary Practice is a wide ranging one, implying as it does, compliance with

More information

Summary of Product Characteristics

Summary of Product Characteristics Summary of Product Characteristics 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Carofertin 10 mg/ml Emulsion for injection for cattle and pigs 2 QUALITATIVE AND QUANTITATIVE COMPOSITION 1 ml contains: Active

More information

Prescribing Guidelines for Outpatient Antimicrobials in Otherwise Healthy Children

Prescribing Guidelines for Outpatient Antimicrobials in Otherwise Healthy Children Prescribing Guidelines for Outpatient Antimicrobials in Otherwise Healthy Children Prescribing Antimicrobials for Common Illnesses When treating common illnesses such as ear infections and strep throat,

More information

SUMMARY OF PRODUCT CHARACTERISTICS. Procaine penicillin Dihydrostreptomycin Sulfate

SUMMARY OF PRODUCT CHARACTERISTICS. Procaine penicillin Dihydrostreptomycin Sulfate SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Streptacare Suspension for Injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Active Substance: Each ml contains: Procaine

More information

MODEL STANDARDS FOR PET SHOP LICENCE CONDITIONS

MODEL STANDARDS FOR PET SHOP LICENCE CONDITIONS ANIMAL WELFARE ACT 2006 PET ANIMALS ACT 1951 MODEL STANDARDS FOR PET SHOP LICENCE CONDITIONS Reptiles, Amphibians, Fish and other Aquatic Invertebrates h&e314v2 The Standard Licence Conditions N.B. Reptiles,

More information

PGD previously approved: October This direction was authorised on: October The direction will be reviewed by: October 2019

PGD previously approved: October This direction was authorised on: October The direction will be reviewed by: October 2019 Patient Group Direction for the supply of Trimethoprim 200mg tablets for the treatment of women with uncomplicated urinary tract infections by Pharmacists working within NHS Borders Community Pharmacies.

More information

Patient Group Direction for METRONIDAZOLE (Version 03) Valid From 1 June May 2020

Patient Group Direction for METRONIDAZOLE (Version 03) Valid From 1 June May 2020 Version Control This PGD has been agreed by the following organisations FCMS PDS Medical Doncaster CCG Lancashire CCGs including East Lancashire, Fylde and Wyre and North Lancashire CCGs Change history

More information

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1/18

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1/18 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1/18 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Oncept IL-2 lyophilisate and solvent for suspension for injection for cats 2. QUALITATIVE AND QUANTITATIVE COMPOSITION

More information

SUMMARY OF PRODUCT CHARACTERISTICS. Lincomycin (as Lincomycin hydrochloride) Neomycin (as Neomycin sulphate) Excipients Disodium edetate

SUMMARY OF PRODUCT CHARACTERISTICS. Lincomycin (as Lincomycin hydrochloride) Neomycin (as Neomycin sulphate) Excipients Disodium edetate SUMMARY OF PRODUCT CHARACTERISTICS AN: 00221/2013 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Lincocin Forte S Intramammary Solution 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Active substances Lincomycin

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Acecare 2mg/ml Solution for Injection for Dogs and Cats 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1 ml of solution contains

More information

= 0.5 mg. In vitro toxin neutralisation test based on haemolysis of sheep erythrocytes. For a full list of excipients, see section 6.1.

= 0.5 mg. In vitro toxin neutralisation test based on haemolysis of sheep erythrocytes. For a full list of excipients, see section 6.1. 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Covexin 8 Suspension for injection for sheep and cattle 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Active substances: Potency value/quantity/ml C. perfringens

More information

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS. Medicinal product no longer authorised

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS. Medicinal product no longer authorised ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT BTVPUR AlSap 1 suspension for injection for sheep and cattle. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each dose

More information

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Ophtocycline 10 mg/g eye ointment for dogs, cats and horses (AT, BE, BG, CY, CZ, EL, ES, HR, HU, IE, IT, LU, NL,

More information

Ear drops suspension. A smooth, uniform, white to off-white viscous suspension.

Ear drops suspension. A smooth, uniform, white to off-white viscous suspension. SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT OTOMAX EAR DROPS SUSPENSION 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml of the veterinary medicinal product contains:

More information

Oral and intestinal candidiasis. As adjuvant treatment with other local nystatin preparations to prevent reinfection.

Oral and intestinal candidiasis. As adjuvant treatment with other local nystatin preparations to prevent reinfection. 1. NAME OF THE MEDICINAL PRODUCT Nystatin Orifarm, 100 000 IU/ml oral suspension 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1 ml contains 100 000 IU nystatin. Excipients with known effect: - Methyl parahydroxybenzoate

More information

ruma Cattle Responsible use of antimicrobials in Cattle production GUIDELINES

ruma Cattle Responsible use of antimicrobials in Cattle production GUIDELINES ruma RESPONSIBLE USE OF MEDICINES IN AGRICULTURE ALLIANCE GUIDELINES Cattle Responsible use of antimicrobials in Cattle production RUMA guidelines for the responsible use of antimicrobials by cattle farmers

More information

Summary of Product Characteristics

Summary of Product Characteristics Summary of Product Characteristics 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Malaseb shampoo for dogs and cats 2 QUALITATIVE AND QUANTITATIVE COMPOSITION 1 ml contains: Active substances: Chlorhexidine

More information

LANAnC64 - SQA Unit Code HA8F 04 Carry out the implantation of a microchip in an animal

LANAnC64 - SQA Unit Code HA8F 04 Carry out the implantation of a microchip in an animal LANAnC64 - SQA Unit Code HA8F 04 Carry out the implantation of a microchip in an animal Overview This standard covers carrying out the implantation of a microchip in an animal. It includes preparation,

More information

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Pentofel 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Per dose of 1ml: Active components Inactivated Feline Panleukopenia

More information

SUMMARY OF PRODUCT CHARACTERISTICS. Pentoject, Pentobarbitone Sodium 200 mg/ml Solution for Injection

SUMMARY OF PRODUCT CHARACTERISTICS. Pentoject, Pentobarbitone Sodium 200 mg/ml Solution for Injection SUMMARY OF PRODUCT CHARACTERISTICS Revised: June 2018 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Pentoject, Pentobarbitone Sodium 200 mg/ml Solution for Injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION

More information

PACKAGE LEAFLET Page 1 of 6

PACKAGE LEAFLET Page 1 of 6 PACKAGE LEAFLET Page 1 of 6 Package leaflet: Information for the patient Desloratadine Mylan 5 mg film-coated tablets desloratadine Read all of this leaflet carefully before you start taking this medicine

More information

GUIDANCE FOR VETERINARY SURGEONS. Use of norethisterone for oestrus suppression in racing bitches in Great Britain

GUIDANCE FOR VETERINARY SURGEONS. Use of norethisterone for oestrus suppression in racing bitches in Great Britain GUIDANCE FOR VETERINARY SURGEONS Use of norethisterone for oestrus suppression in racing bitches in Great Britain The Veterinary Medicines Directorate (VMD) has confirmed that norethisterone, an authorised

More information

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT CYTOPOINT 10 mg solution for injection for dogs CYTOPOINT 20 mg solution for injection for dogs CYTOPOINT 30 mg

More information

ANNEX III LABELLING AND PACKAGE LEAFLET

ANNEX III LABELLING AND PACKAGE LEAFLET ANNEX III LABELLING AND PACKAGE LEAFLET 1 A. LABELLING 2 PARTICULARS TO APPEAR ON THE OUTER PACKAGE AND THE IMMEDIATE PACKAGE Card box and package leaflet for brown glass bottle (Type 1) 1. NAME OF THE

More information

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Distocur 34 mg/ml Oral suspension for cattle. Distocur.vet 34 mg/ml Oral suspension for cattle. (DK, NO, SE) 2.

More information

PART IB1 SUMMARY OF PRODUCT CHARACTERISTICS OCTACILLIN

PART IB1 SUMMARY OF PRODUCT CHARACTERISTICS OCTACILLIN PART IB1 SUMMARY OF PRODUCT CHARACTERISTICS OCTACILLIN 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Octacillin 800 mg/g powder for use in drinking water for chickens NL: Octacillin 800 mg/g poeder voor gebruik

More information

Volume. December Infection. Notes. length of. cases as 90% 1 week. tonsillitis. First Line. sore throat / daily for 5 days. quinsy >4000.

Volume. December Infection. Notes. length of. cases as 90% 1 week. tonsillitis. First Line. sore throat / daily for 5 days. quinsy >4000. Volume 8; Number 22 LINCOLNSHIRE GUIDELINES FOR THE TREATMENT OF COMMONLYY OCCURRING INFECTIONS IN PRIMARY CARE: WINTER 2014/15 In this issue of the PACE Bulletin we present an update of our Guidelines

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Rycarfa 100 mg tablets for dogs (BE, DE, ES, FR, IE, IT, NL, PT, UK) Rycarfa vet 100 mg tablets for dogs (DK, FI) Carprox

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Amfipen LA 100 mg/ml suspension for injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Active substance: Each ml contains:

More information

WORLD ANTIBIOTIC AWARENESS WEEK

WORLD ANTIBIOTIC AWARENESS WEEK # AntibioticResistance WORLD ANTIBIOTIC AWARENESS WEEK 14-20 NOVEMBER 2016 2016 CAMPAIGN TOOLKIT TABLE OF CONTENTS Why we need a global campagin... Campagin objectives... Key messages... Calls to action

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS [Version 8, 10/2012] ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS (Based on the current SPC of the reference product Baytril RSI 100 mg/ml Injektionslösung für Rinder und Schweine) 1 1. NAME OF THE VETERINARY

More information

MARBOCYL 10% SUMMARY OF PRODUCT CHARACTERISTICS

MARBOCYL 10% SUMMARY OF PRODUCT CHARACTERISTICS MARBOCYL 10% SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT MARBOCYL 10%, solution for injection for cattle and swine 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Marbofloxacin...100.0

More information

Bacteria become resistant to antibiotics- not humans or animals.

Bacteria become resistant to antibiotics- not humans or animals. July 2017 Dear Colleague, World Antibiotic Awareness Week - National Community Pharmacy Public Health Campaign 2017 Please find enclosed information and resources for the next contractual national community

More information

Summary of Product Characteristics

Summary of Product Characteristics Summary of Product Characteristics 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Selectan 300 mg/ml solution for injection for cattle and swine. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains:

More information

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Clevor 30 mg/ml eye drops, solution in single-dose container for dogs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION

More information

For the treatment of infections caused by a wide range of Gram-positive and Gramnegative pathogenic bacteria including:

For the treatment of infections caused by a wide range of Gram-positive and Gramnegative pathogenic bacteria including: SUMMARY OF PRODUCT CHARCTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Amoxycare Suspension for Injection 15% w/v 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains Active Substance(s)

More information

GUIDE TO THE PROFESSIONAL PRACTICE STANDARD

GUIDE TO THE PROFESSIONAL PRACTICE STANDARD GUIDE TO THE PROFESSIONAL PRACTICE STANDARD Use of Compounded Products in Veterinary Practice Published: December 2014 Introduction The College s Professional Practice Standard: Use of Compounded Products

More information

Author - Dr. Josie Traub-Dargatz

Author - Dr. Josie Traub-Dargatz Author - Dr. Josie Traub-Dargatz Dr. Josie Traub-Dargatz is a professor of equine medicine at Colorado State University (CSU) College of Veterinary Medicine and Biomedical Sciences. She began her veterinary

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Xylacare 2% w/v Solution for Injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Active substances Qualitative composition

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Tilmovet 250 mg/ml Concentrate for Oral Solution (BE, BG, CZ, EL, HU, IE, NL, PL, RO, UK) for pigs, chickens, turkeys and

More information

The Community Pharmacy and Veterinary Medicines. The Opportunities

The Community Pharmacy and Veterinary Medicines. The Opportunities The Community Pharmacy and Veterinary Medicines The Opportunities Classifications of Medicines POM-V Prescription only medicine Veterinarian [formerly POM]. POM-VPS Prescription only medicine Veterinarian,

More information

SHARED CARE GUIDELINE FOR GLYCOPYRROLATE 1. Aim/Purpose of this Guideline

SHARED CARE GUIDELINE FOR GLYCOPYRROLATE 1. Aim/Purpose of this Guideline SHARED CARE GUIDELINE FOR GLYCOPYRROLATE 1. Aim/Purpose of this Guideline 1.1. This guideline applies to medical, nursing and pharmacy staff in the safe and appropriate prescription and administration

More information

PACKAGE LEAFLET: INFORMATION FOR THE USER. AMOXICILLIN 250mg and 500mg CAPSULES BP Amoxicillin (as amoxicillin trihydrate)

PACKAGE LEAFLET: INFORMATION FOR THE USER. AMOXICILLIN 250mg and 500mg CAPSULES BP Amoxicillin (as amoxicillin trihydrate) PACKAGE LEAFLET: INFORMATION FOR THE USER AMOXICILLIN 250mg and 500mg CAPSULES BP Amoxicillin (as amoxicillin trihydrate) Read all of this leaflet carefully before you start taking this medicine because

More information

Summary of Product Characteristics

Summary of Product Characteristics Summary of Product Characteristics 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Melosolute 20 mg/ml solution for injection for cattle, pigs and horses. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION One ml contains:

More information

GENTAMICIN SULFATE- gentamicin sulfate solution/ drops Pacific Pharma, Inc GENTAMICIN SULFATE ophthalmic s olution, USP 0.

GENTAMICIN SULFATE- gentamicin sulfate solution/ drops Pacific Pharma, Inc GENTAMICIN SULFATE ophthalmic s olution, USP 0. GENTAMICIN SULFATE- gentamicin sulfate solution/ drops Pacific Pharma, Inc. ---------- GENTAMICIN SULFATE ophthalmic s olution, USP 0.3% sterile DESCRIPTION Gentamicin sulfate ophthalmic solution, USP

More information

Amoxicillin 250mg Hard Capsules Amoxicillin 500mg Hard Capsules

Amoxicillin 250mg Hard Capsules Amoxicillin 500mg Hard Capsules Package leaflet: Information for the user Amoxicillin 250mg Hard Capsules Amoxicillin 500mg Hard Capsules Amoxicillin Read all of this leaflet carefully before you start taking this medicine because it

More information